Global Intranasal Drug Delivery Industry

Global Intranasal Drug Delivery Industry

  • April 2021 •
  • 307 pages •
  • Report ID: 5436898 •
  • Format: PDF
Abstract:
- Global Intranasal Drug Delivery Market to Reach $59.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Intranasal Drug Delivery estimated at US$44.7 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2027, growing at a CAGR of 4.1% over the analysis period 2020-2027. Spray, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$19.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Drop segment is readjusted to a revised 5% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $12.1 Billion, While China is Forecast to Grow at 6.3% CAGR
- The Intranasal Drug Delivery market in the U.S. is estimated at US$12.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.8 Billion by the year 2027 trailing a CAGR of 6.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.
- Gel Segment to Record 3.6% CAGR
- In the global Gel segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$8 Billion in the year 2020 will reach a projected size of US$10 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$7.8 Billion by the year 2027, while Latin America will expand at a 4.5% CAGR through the analysis period.

- Select Competitors (Total 64 Featured) -
  • Aegis Therapeutics LLC
  • AptarGroup, Inc.
  • AstraZeneca Plc
  • Becton Dickinson and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Marina Biotech, Inc.
  • MedImmune, Inc.
  • Merck & Co., Inc.
  • Nemera
  • Novartis AG
  • OptiNose US Inc.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.